Updated:
Regeneron Ventures
Regeneron Ventures, backed by $500M from Regeneron Pharmaceuticals, invests independently in early-stage healthcare and AI companies.
Regeneron Ventures
Regeneron Ventures is the venture arm of Regeneron, based in Tarrytown, New York. It invests in small and medium-sized companies. Regeneron Ventures has made 13 investments, including a Series A investment in Think Bioscience on January 20, 2026.
General information
Firm type
Venture Capital
Year founded
2023
AUM
$500M – $1B (Altss estimate)
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Jay Markowitz
Senior Managing Director
Michael Aberman
Senior Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at Regeneron Ventures?
Senior Managing Directors Jay Markowitz and Michael Aberman jointly lead the firm. Markowitz spent over a decade at Takeda Ventures, and Aberman previously served as an analyst and portfolio manager at The Column Group. The investment committee operates independently of Regeneron Pharmaceuticals' corporate development team.
Are Regeneron Ventures' portfolio companies required to partner with Regeneron Pharmaceuticals?
No. Regeneron Ventures invests with a financial return mandate, not a strategic synergy mandate. Portfolio companies are not obligated to align with Regeneron's internal R&D programs or enter into licensing agreements with the parent corporation.
What is the relationship between Regeneron Ventures and Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals is the sole limited partner in Regeneron Ventures, providing a $500 million capital commitment. However, the venture firm operates with its own investment committee, independent decision-making authority, and a mandate to invest across the life sciences ecosystem without preferential treatment toward the parent company.
What investment stages does Regeneron Ventures target?
The firm focuses on early-stage companies, typically participating in and leading Series A and B rounds. It maintains reserves for follow-on investments and can write checks sized to lead competitive rounds, placing it in direct competition with established life sciences venture firms.
Does Regeneron Ventures invest in therapeutics or drug development companies?
Regeneron Ventures emphasizes the tools, technologies, and platforms that improve drug discovery and development—such as AI/ML applications, automation, and data science—rather than directly investing in therapeutic asset companies that might compete with its parent's pipeline.
How does Regeneron Ventures source deal flow?
Deal sourcing combines the networks of its Senior Managing Directors, both of whom have deep ties in venture capital and biotechnology, with inbound opportunities generated through Regeneron's brand recognition. The firm does not publicly describe a formal academic-institution or accelerator-sourcing partnership.
Is Regeneron Ventures raising external LP capital?
No. The firm was capitalized entirely by Regeneron Pharmaceuticals and has not indicated any plans to open the fund to external limited partners. This single-LP structure allows the team to deploy capital without the time and overhead of multi-year fundraising cycles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: